Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 171Neoplasms 166Colorectal Neoplasms 152Neoplasm Metastasis 125Prostatic Neoplasms 118Recurrence 117Leukemia, Myeloid, Acute 117Melanoma 116Pancreatic Neoplasms 114Ovarian Neoplasms 109Multiple Myeloma 105Lung Neoplasms 94Stomach Neoplasms 92Triple Negative Breast Neoplasms 86Squamous Cell Carcinoma of Head and Neck 86Lymphoma 77Glioblastoma 77Lymphoma, Non-Hodgkin 76Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Carcinoma, Hepatocellular 58Endometrial Neoplasms 56Advanced Solid Tumor 56Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

enzalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Prostate Cancer × 1 year × Clear all
NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
212 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡